chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swelling, fever, nausea, vomiting, joint pain, visual impaired, fatigue, myalgia. 11/30/09 DC summary received and hosp recs received for date 10/8/09 to 10/12/09. DX: allergic reaction to flumist. Influenza. Presenting sx: pt states received vax and approx 3hrs later c/o sudden swelling around neck, difficulty breathing, the following day pt states face swelling, rash upper torso. Was tx in ER and later returned for worsening of sx. Currently presenting to this ER visit w. myalgias, fever, chills, SOB, weakness. Assessment: fever, rash, facial swelling.
Pt vaccinated with meruvax II developed flu-like symptoms followed by lower spine, lt knee, ankle & heel pain w/stiffness & generalized bone pain. Treated w/Ibuprofen (Motrin).
Pt reports having a sensation of throat tightness during her waiting period after the vaccine. However, she did not tell anyone at the site, and was able to breathe well. She left the site without informing anyone.  She continue to have the sensation for that day, then it resolved. However, since that time she has had an unusual feeling of ill-defined shortness of breath and frequent throat clearing
p/ receiving DPT #2 infant developed fever 103.4 for 4 days and extreme lethargy
Started to feel really sick; Feverish; Joint pain; Exhausted; This is a spontaneous report from a contactable consumer (patient herself) via sponsored program Support. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 27Feb2021 as Dose 2, Single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unknown date as Dose 1, Single for COVID-19 immunization. On an unknown date in 2021, she started to feel really sick. She said she's feeling feverish, having joint pain and so exhausted. Added that she took Tylenol after the 2nd dose. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This spontaneous report was received from a registered nurse referring to a 14 year old male patient. The patient's concomitant medication, pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On 26-SEP-2017, the patient was vaccinated with either GARDASIL lot # N000326, expiration date 14-OCT-2019 or GARDASIL 9 lot # N000326, expiration date: not reported (strength, dose, dose number and route of administration were not provided) for prophylaxis which were improperly stored (incorrect product storage). This is one of several reports received from the same source.; Sender's Comments: US-009507513-1709USA008666:
Received vaccination 6/28/12 - went on vacation 7/4/12 experienced severe fatigue. By 7/11/12 numbness/tingling (R) hands & feet. 7/14/12 - trouble walking. 7/26 dx Guillain Barre. Current in PT/OT also receiving IgG.
Usual reaction, sore arm, chills, headache. Resolved in 48 hours.  Then,  on 3/10/21, I had terrible intestinal cramping, followed by vomiting, blood discharge from rectum.  ER on 3/11/21 and hospitalized for 4 days. Diagnosis was Ischemic Colitis caused by low blood pressure. Never had this before and wondering if the low blood pressure and resulting colitis could have been caused by the vaccine
None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer (Dose 1 and Lot number (EH9899)) on 20-Dec-2020. Past adverse reactions to the above products included No adverse event with Pfizer.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment drugs were reported.   This case was linked to MOD-2021-395985 (Patient Link).
I started experiencing shortness of breathe and chest tightness. My doctor sent me for some additional testing and was later sent to the hospital for a blood clot in my lungs. I stayed in the hospital 2/18-2/21 and I am currently on blood thinners for 6 months.
I experienced micro blood clots, all of my toes on my left foot had little micro blood clots.
Vomiting and Diarrhea day after vaccine.  6 days after shot blood clot and stroke, currently in ICU.
rash; This case was reported by a physician via sales rep and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The patient received Shingrix at the pharmacy and had a rash afterwards on her arm.
Dizziness at injection time.  Fever the next day.  Terrible full body rash, raised hives, itchiness, Swollen uvula, difficulty breathing, dizziness, excessive thirst. Ended up in Emergency room. Swollen hands and limbs
Arm hurt immediately , few hours later severe sweats, fever ,severe migraine like headache , complete body ache lasted 2 days
Narrative:  Patient received first COVID vaccine on 2/11 where he reports feeling extremely weak and having hard time with words. Patient has also been falling since he returned home. Denies facial, lip, or tongue swelling, rash, itching, chest pain. Patient was instructed to call 911.
Back Pain. Patient received TRUMENBA and within 4 to 6 hours after vaccine. Patient complained of feeling feverish and back pain. Back pain is still persistent and nothing is helping with the pain. Plan Ice to back, Ibuprofen 3 tabs q 6 hr X 2 today and X 3 tomorrow, then 2 tabs 2x on Sunday. Wean as tolerated. Rest over weekend. Out of gym x 3 days. Call if needs excuse for rest of week. Call if pain persisting another week.
Patient complains of sore arm, which leads to difficulty showering, after receiving FLUZONE High Dose vaccine.
A-Fib; Dysautonomia (unspecified, in process of diagnosis); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old male patient received BNT162b2 (BNT162B2), on 21Jun2022 as dose 3 (booster), single (Lot number: FM7553) at the age of 41 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. No known allergies. Concomitant medication(s) in 2 weeks included: METOPROLOL; ASPRIN. No other vaccine in four weeks. Vaccination history included: pfizer covid 19 vaccine (Dose Number: 2, Batch/Lot No: ER8733, Location of injection: Arm Left), administration date: 05Apr2021, when the patient was 39-year-old, for covid-19 immunization; pfizer covid 19 vaccine (Dose Number: 1, Batch/Lot No: 6206, Location of injection: Arm Left), administration date: 14Mar2021, when the patient was 39-year-old, for covid-19 immunization. The following information was reported: ATRIAL FIBRILLATION (hospitalization, disability), outcome "not recovered", described as "A-Fib"; AUTONOMIC NERVOUS SYSTEM IMBALANCE (hospitalization, disability), outcome "not recovered", described as "Dysautonomia (unspecified, in process of diagnosis)". The patient was hospitalized for atrial fibrillation, autonomic nervous system imbalance (hospitalization duration: 3 day(s)). The events "a-fib" and "dysautonomia (unspecified, in process of diagnosis)" required physician office visit and emergency room visit. No Covid prior vaccination. Covid was tested post vaccination. Covid test type post vaccination was nasal swab. Therapeutic measures for the events included Beta Blockers, Compression Socks, TBD.
Sore arm; I also had numbness on the left side of my lower lip, upper lip and left nostril; itchiness on the back of my head and a little bit of itchiness on my arm; Dying of the hair; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported; Expiration Date: 31Aug2021), via an unspecified route of administration, administered in left arm on 20May2021 as 1st dose, single dose for covid-19 immunization. The medical history and concomitant medications were not reported. On an unspecified date after the vaccination the patient experienced a sore arm and she put ice on it. She also had numbness, like when you go to the dentist, on the left side of my lower lip, upper lip and left nostril. She also had itchiness on the back of head and a little bit of itchiness on arm. Most of the itchiness was on the back of her head though. The patient was not sure if there was something with her permanent or dying of the hair and the vaccine that may have caused the itching. The patient was scheduled second dose on 10Jun2021. She enquired about if she could have her second dose. The outcome of the events was unknown.  Information on lot/batch number has been requested.
This case was reported by a physician via sales rep and described the occurrence of rash in a adult patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced rash, injection site pain and injection site induration. On an unknown date, the outcome of the rash, injection site pain and injection site induration were unknown. It was unknown if the reporter considered the rash, injection site pain and injection site induration to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that the patient developed rash around neck and shoulder within 24 hours of getting SHINGRIX along with pain induration at injection site. All questions were asked to reporter but provided limited information. The GlaxoSmithKline field representative gave permission to contact primary reporter for further details.
Patient c/o of (L) arm pain that has continued since she got injection on 10/5/10.
On Mon. 4/12/21, around 7:00am, in the shower, I discovered Swelling/Edema (equivalent to a jelly filled-doughnut) in my Right Arm Pit, that was tender to the touch and visually noticeable in terms of protrusion size, with slight discoloration.
Body aches, chills, fever. On Saturday March 27, I woke up and noticed I had no sense of smell. Later in the day, my sense of taste seemed deadened. I had an odd metallic taste in my mouth. By Monday all symptoms were gone.
Approximately 10 minutes after receiving the vaccine patient reported feeling thickness in the back of the throat. Diphenhydramine 25 mg was administered. Approximately 25 minutes after vaccination patient reported neck tightening and another dose of diphenhydramine 25 mg was administered by mouth. Patient reports that it feels like the pill was not going down her throat. Rapid response was called and patient was transported to the Emergency Department for further evaluation.
High fever 102 started at 2:30AM on the 7th . I had riggers, my whole body was out of control shaking like a seizure. I was extremely confused I had a 8/10 headache. I had serve fatigue.  This last about 24 hours then went away I finally got out of bed the next day about 4:30PM.
was not feeling well; jaw locking; chills; numbness, in finger and toes; headaches; dry throat; This is a spontaneous report from a contactable consumer. A 69-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number unknown) via an unspecified route of administration on 27Feb2021 at single dose for COVID-19 immunisation. Relevant medical history and concomitant medications were not reported. The patient was not feeling well, had jaw locking, chills, numbness in finger and toes, headaches and very dry throat. The events were non-serious. Outcome was unknown.  No follow-up attempts are possible; information on lot/batch number cannot be obtained.
Fever at 102.2; chills; stomach cramping; sore neck; sore at site of injection; minor headache; runny nose; This is a spontaneous report from a contactable consumer reported for self. This 37-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot#: EN 5318) at single dose on 16Feb2021 10:00 for COVID-19 immunisation. The first dose was on 26Jan2021 at 11:00 AM (Lot#: EN5318) in left arm. Medical history was not reported. Allergies to medications, food, or other products was none known. Concomitant medication included vitamin D. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had fever at 102.2 and chills, stomach cramping, sore neck, sore at site of injection, minor headache and runny nose on 17Feb2021 12:00 AM. There was no treatment received for the adverse event. This was a non-serious report. The events did not result in death, not life threatening, not caused/prolonged hospitalization, no disabling/incapacitating, no congenital anomaly/birth defect. Patient was recovering from the events.   No follow-up attempts are possible. No further information is expected.
1 dose of expired Moderna COVID 19 vaccine was administered to 1 patient; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (1 dose of expired Moderna COVID 19 vaccine was administered to 1 patient) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 054C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (1 dose of expired Moderna COVID 19 vaccine was administered to 1 patient). On 04-Aug-2021, EXPIRED PRODUCT ADMINISTERED (1 dose of expired Moderna COVID 19 vaccine was administered to 1 patient) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported by the reporter.  No treatment information provided.
No other AE details available at this time; Caller reported temperature excursion.; This spontaneous report was received from a registered nurse, referring to a 12-months-old patient of unknown gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies and concomitant medications were not provided.   On 21-DEC-2020, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX), at a dose of 0.5 milliliter (ml), as prophylaxis (formulation, strength, vaccination scheme, route of administration and anatomical site of vaccination were not reported; lot number T017688, which has been verified to be valid, expiration date reported and validated as 21-MAY-2022). The vaccine administered experienced a temperature excursion of -13.3 degrees Celsius (C), for a time frame of 4 hours and 15 minutes, as recorded by a data logger (product storage error). There was no previous temperature excursion reported. No additional adverse events were reported.       This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2012USA013093: US-009507513-2012USA013095: US-009507513-2012USA013524: US-009507513-2012USA013539:
couldn't get their 2nd dose.; Flu; coughing; bronchitis; This is a spontaneous report from a contactable consumer (patient's wife) re-ported for a 82-year-old male patient (reporter's husband) received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: PFEN6207 and expiry date was not reported), via an unspecified route of administration, in Arm Right, on 18Mar2021 at 11:30 (age at vaccination: 82 years), as dose 1, single dose for COVID-19 immunization. The patient's medical history included ongoing diabetes mellitus (diagnosed at 35 years old), high blood pressure (diagnosed approximately in 1960), and Blood cholesterol (diagnosed approximately in 1960). Concomitant medications were not reported. The patient did not receive any vaccine prior vaccinations (within 4 weeks). The reporter reported that on an unspecified date, the patient got sick with flu and bronchitis. The patient had coughing already and got checked out and were ok. The reporter clarified that the patient got sick with flu and couldn't get their 2nd dose. The reporter did not know the date the 2nd dose was supposed to be given. The events did not require a visit to emergency room and physician office. There were not relevant tests. Outcome of the event coughing was recovered on an unspecified date and for other events, it was unknown.  No follow-up attempts are needed. No further information is expected.
Fatigue, Blurred vision, Eyes ral tired, Feels drunk or heavily medicated, Unable to drive due to inability to focus visually.
Redness, swelling,  itchy and tender to the touch after 7 days of vaccination.
12 year old received 0.25ml Moderna booster > 5 months after 2 primary Pfizer doses.  Next day side effects: Swollen  and painful armpit, chills
Patient reported a hot spot on her left arm,  2 or 3 inches below the injection site.  She said it just showed up the morning on the January 15th.  I advised cool compresses to the site. She said no fever.  She followed up with her physician, who subsequently ordered an antibiotic for cellulits.
104 F fever, muscle aches, fatigue, headache.  all lasting 36 hours.  they have since resolved
This spontaneous report as received from a pharmacist refers to a 67 years old male patient with no pertinent medical history. The patient was vaccinated with a dose of ZOSTAVAX on 12-JUL-2012 (Lot# reported as 0240AE, expired date 13-MAR-2015, dose and route not reported). No other co-suspects were reported. No concomitant medications were reported. On 12-JUL-2012 the patient was vaccinated and immediately became dizzy and disoriented. At the time of this report the patient was resting in the pharmacy. The patient sought medical attention in the pharmacy. No lab diagnostics studies performed. No treatment was given. The patient had not recovered. Additional information has been requested.
This spontaneous report was received from a Registered Medical Assistant (R.M.A.) referring to a 20 year old patient of unknown gender. No concurrent conditions or medical history were reported. On 11-MAY-2015, the patient accidentally was vaccinated with a pediatric dose of VAQTA, 0.5 ml, intramuscular, instead of an adult dose. No concomitant therapy was provided. No adverse effect was reported. Additional information has been requested.
Pain throughout arm starting approximately 3 minutes after administration patient felt faint, was seated and provided an ice pack, water, and food until she felt better. Pain began to subside within 30 minutes.
I received my Covid booster on Thursday, November 18. All three doses were Pfizer. On Friday and Saturday, I was in a daze and alternately way too hot and way too cold. Then on Sunday morning I couldn't move my arm. The entire outer half of my upper arm where I had received the injection was extremely swollen, red, hot, hard, and painful. Monday it was still bad, so I called my doctor's office and the nurse said to come in. The doctor said to switch from Tylenol to Aleve and to keep applying a cold pack and that it would go away in less then two weeks. She said maybe get Moderna if we have to get more boosters in the future, but I've read that covid arm is more common with Moderna. I don't know when I've had a bad a pain as that (9/10) for 2 whole days. It has been slowly getting better every day. Range of motion was back by Wednesday the 24th. Now its Monday the 29th, and my arm is still hot, itchy, and retaining some water.
This non-serious initial spontaneous case, was received on 06-Nov-2017 from a pharmacist, concerning 63-year-old, adult, female patient. On 05-NOV-2017, the patient was administered with AFLURIA (dose, route of administration, anatomical location, batch number, expiry date: not reported). It was reported that the AFLURIA was at a temperature of 57 F for a few hours (lasted for 4 hours). Hence, vaccine was outside the recommended range which was administered to the patient (explicitly coded as Incorrect product storage and drug administration error). The reporter assessed the events as non-serious.
Breakthrough COVID-19 infection. Lasted for 10 days Cough Congestion Fever Chills Sweats Body aches Fatigue Brain Fog
Client received his booster vaccine weeks more than 2 weeks early.   His booster was due no sooner than 12/7/21.
Off label use; Booster; It was reported the patient woke up with a bad case of tachycardia and stayed in the hospital; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): 2022NVX-US-000004115 (Novavax).  A 19-year-old male patient received BNT162b2 (BNT162B2), on 26Feb2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 19 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, UNKNOWN MANUFACTURER), for Covid-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE, UNKNOWN MANUFACTURER), for COVID-19 Immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE , UNKNOWN MANUFACTURER), for Covid-19 immunization; Covid-19 vaccine (DOSE 4 (BOOSTER), SINGLE , UNKNOWN MANUFACTURER), for Covid-19 immunization. The following information was reported: IMMUNISATION (hospitalization) with onset 26Feb2022, outcome "unknown", described as "Booster"; OFF LABEL USE (hospitalization) with onset 26Feb2022, outcome "unknown"; TACHYCARDIA (hospitalization) with onset 2022, outcome "recovered" (2022), described as "It was reported the patient woke up with a bad case of tachycardia and stayed in the hospital". Clinical course: On 04Nov2022, it was reported that a patient started treatment on 26Feb2022 with Pfizer BioNTech COVID-19 Vaccine 3rd booster dose for COVID-19 immunisation. It was reported the patient woke up with a bad case of tachycardia and stayed in the hospital. It resolved within 2 days.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.